0701 GMT - Australia-based biotech company CSL, which collects plasma in the U.S. and manufactures many plasma-based products at plants in Europe, would likely need to raise prices by between 4% to 5.1% to offset Trump's planned tariffs on pharmaceuticals, say Jefferies analysts. While it isn't clear exactly how the Trump pharmaceutical tariffs will work, the good news for CSL is that over time it may be able to move plasma product manufacturing from high tariff locations in Europe to lower tariff areas like Australia, say David Stanton and Vanessa Thomson. This will put it in a slightly better position than its major European competitors. But in general, "plasma companies may see difficulties transferring complex, expensive operations at plants that can take years to build," they add. CSL shares ended 5% lower. (mike.cherney@wsj.com; @Mike_Cherney)
(END) Dow Jones Newswires
April 09, 2025 03:01 ET (07:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.